There is more than one kind of myofibroblast: analysis of CD34 expression in benign, in situ, and invasive breast lesions

Aims: Smooth muscle actin (SMA) positive myofibroblasts have been implicated in tumour invasion; however, acquisition of SMA is not limited to peritumorous fibroblasts and other changes in fibroblasts may be more specifically related to the malignant environment. CD34 is a sialomucin expressed by normal breast fibroblasts but lost in invasive carcinomas. The aim of this study was to establish the relation between CD34 and SMA expression in breast fibroblasts and to analyse whether loss of CD34 is specific for invasive disease. Methods: Immunohistochemistry for CD34 and SMA was performed on 135 cases including 10 normal, 10 fibroadenomas, 40 infiltrating ductal carcinomas, 55 cases of ductal carcinoma in situ (DCIS), and 20 radial scar/complex sclerosing lesions. The relation between staining pattern and histopathological features was recorded as positive, negative, or reduced. Results: Fibroblasts around all normal duct–lobule units and those showing epithelial hyperplasia were CD34 positive and mainly SMA negative. In fibroadenomas, fibroblasts retained CD34 but acquired SMA expression. In contrast, fibroblasts around invasive carcinoma were CD34 positive and SMA negative. In DCIS, loss of CD34 was significantly more frequent in high grade tumours than in low or intermediate grade ones (p < 0.001). The acquisition of SMA was seen more frequently than the loss of CD34, particularly in non-high grade DCIS. In all radial scars, fibroblasts were SMA positive but CD34 negative, and a similar pattern was seen in stromal cells in areas of fibrosis following core biopsy. Conclusions: These results show that SMA positive myofibroblasts exhibit variable expression of CD34, indicating that these markers are not coordinately controlled. Loss of CD34 is strongly related to the malignant phenotype, in both invasive and preinvasive disease, but is not entirely specific because radial scar fibroblasts and fibroblasts in reactive fibrosis exhibit a similar phenotype. The functional relevance of altered CD34 expression is unclear but the very focal changes implicate local signalling mechanisms probably of epithelial origin.

[1]  M. Bisceglia,et al.  Benign spindle cell tumors of the mammary stroma: diagnostic criteria, classification, and histogenesis. , 2001, Pathology, research and practice.

[2]  E. Lengyel,et al.  Induction of M(r) 92,000 type IV collagenase expression in a squamous cell carcinoma cell line by fibroblasts. , 1995, Cancer research.

[3]  R. Coleman,et al.  Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  P. Glynn,et al.  Expression of MMP‐2 and MMP‐9, their inhibitors, and the activator MT1‐MMP in primary breast carcinomas , 1999, The Journal of pathology.

[5]  Frederick Grinnell,et al.  Fibroblasts, myofibroblasts, and wound contraction , 1994, The Journal of cell biology.

[6]  J. Silverman,et al.  Mammary fibroadenoma and some phyllodes tumour stroma are composed of CD34+ fibroblasts and factor XIIIa+ dendrophages , 1996, Histopathology.

[7]  R. Steele,et al.  A phase II study of the oral matrix metalloproteinase inhibitor, marimastat, in patients with inoperable gastric cancer , 1998 .

[8]  C. Gilles,et al.  Induction of membrane-type matrix metalloproteinase 1 (MT1-MMP) expression in human fibroblasts by breast adenocarcinoma cells , 1997, Clinical & Experimental Metastasis.

[9]  P. Lindahl,et al.  Not all myofibroblasts are alike: revisiting the role of PDGF‐A and PDGF‐B using PDGF‐targeted mice , 1998, Current opinion in nephrology and hypertension.

[10]  B. Smoller,et al.  Use of CD34 in assessing the relationship between stroma and tumor in desmoplastic keratinocytic neoplasms , 1995, Journal of cutaneous pathology.

[11]  M J Bissell,et al.  Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. , 1996, Physiological reviews.

[12]  G. Colditz,et al.  Radial scars in benign breast-biopsy specimens and the risk of breast cancer. , 1999, The New England journal of medicine.

[13]  K. Cohn,et al.  Evidence for tumor-host cooperation in regulating MMP-2 expression in human colon cancer , 1999, Clinical & Experimental Metastasis.

[14]  G. Stamp,et al.  Expression of gelatinase A and TIMP-2 mRNAs in desmoplastic fibroblasts in both mammary carcinomas and basal cell carcinomas of the skin. , 1993, Journal of clinical pathology.

[15]  G. Silberstein Tumour-stromal interactions: Role of the stroma in mammary development , 2001, Breast Cancer Research.

[16]  A. Lee,et al.  Expression of CD34 and bcl‐2 in phyllodes tumours, fibroadenomas and spindle cell lesions of the breast , 2001, Histopathology.

[17]  R. Moll,et al.  CD34+ fibrocytes in invasive ductal carcinoma, ductal carcinoma in situ, and benign breast lesions , 2002, Virchows Archiv.

[18]  I. Saiki,et al.  Influence of fibroblasts on the invasion and migration of highly or weakly metastatic b16 melanoma cells , 1994, International journal of cancer.

[19]  G. Ayala,et al.  Stromal cells promote angiogenesis and growth of human prostate tumors in a differential reactive stroma (DRS) xenograft model. , 2002, Cancer research.

[20]  K. Yamazaki,et al.  Ultrastructural and immunohistochemical observations on intralobular fibroblasts of human breast, with observations on the CD34 antigen. , 1995, Journal of submicroscopic cytology and pathology.

[21]  M. Gleave,et al.  Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. , 1991, Cancer research.

[22]  L. Matrisian,et al.  Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. , 1996, The American journal of pathology.

[23]  B. Chauffert,et al.  In vivo and in vitro invasiveness of a rat colon‐cancer cell line maintaining E‐cadherin expression: An enhancing role of tumor‐associated myofibroblasts , 1994, International journal of cancer.

[24]  W. Dupont,et al.  Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease. , 1991, Human pathology.

[25]  M. Lagios Heterogeneity of duct carcinoma in situ (DCIS): relationship of grade and subtype analysis to local recurrence and risk of invasive transformation. , 1995, Cancer letters.

[26]  A. Schor,et al.  Clonal heterogeneity in fibroblast phenotype: Implications for the control of epithelial‐mesenchymal interactions , 1987, BioEssays : news and reviews in molecular, cellular and developmental biology.

[27]  M. Shekhar,et al.  Breast stroma plays a dominant regulatory role in breast epithelial growth and differentiation: implications for tumor development and progression. , 2001, Cancer research.

[28]  F. Lanza,et al.  Structural and functional features of the CD34 antigen: an update. , 2001, Journal of biological regulators and homeostatic agents.

[29]  J. Bergh,et al.  Localization of hyaluronan in normal breast tissue, radial scar, and tubular breast carcinoma. , 1993, Human pathology.

[30]  K. Korach,et al.  Stromal estrogen receptors mediate mitogenic effects of estradiol on uterine epithelium. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[31]  P. Chambon,et al.  A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas , 1990, Nature.

[32]  S. Schnitt,et al.  Radial scars of the breast and breast carcinomas have similar alterations in expression of factors involved in vascular stroma formation. , 2002, Human pathology.

[33]  M. Greaves,et al.  Expression of the CD 34 Gene in Vascular Endothelial Cells , 2003 .

[34]  L. Bobrow,et al.  Angiogenesis and expression of thymidine phosphorylase by inflammatory and carcinoma cells in ductal carcinoma in situ of the breast , 1999, The Journal of pathology.

[35]  H. Harn,et al.  CD34, CD117, and actin expression in phyllodes tumor of the breast. , 2000, The Journal of surgical research.

[36]  S. Lemeshow,et al.  Genetic model of multi-step breast carcinogenesis involving the epithelium and stroma: clues to tumour-microenvironment interactions. , 2001, Human molecular genetics.

[37]  H. Nakayama,et al.  Differential expression of CD34 in normal colorectal tissue, peritumoral inflammatory tissue, and tumour stroma , 2000, Journal of clinical pathology.

[38]  B. Hirschel,et al.  GRANULATION TISSUE AS A CONTRACTILE ORGAN: A STUDY OF STRUCTURE AND FUNCTION , 1972 .

[39]  M. Greaves,et al.  Expression of the CD34 gene in vascular endothelial cells. , 1990, Blood.

[40]  G. Ayala,et al.  Reactive stroma in prostate cancer progression. , 2001, The Journal of urology.

[41]  J. Foidart,et al.  The Role of Stroma in Breast Carcinoma Growth In Vivo , 1998, Journal of Mammary Gland Biology and Neoplasia.

[42]  F. Balkwill,et al.  MMP-2 release and activation in ovarian carcinoma: the role of fibroblasts , 1999, British Journal of Cancer.

[43]  Monique Martin,et al.  Role of stromal myofibroblasts infiltrating colon cancer in tumor invasion. , 1996, Pathology, research and practice.

[44]  J. Goldblum,et al.  Sarcomas arising in dermatofibrosarcoma protuberans: a reappraisal of biologic behavior in eighteen cases treated by wide local excision with extended clinical follow up. , 2000, The American journal of surgical pathology.

[45]  S. Bell,et al.  Changes in tenascin-C isoform expression in invasive and preinvasive breast disease. , 2002, Cancer research.